TW200302105A - Use of PDE5 inhibitors in the treatment of scarring - Google Patents
Use of PDE5 inhibitors in the treatment of scarring Download PDFInfo
- Publication number
- TW200302105A TW200302105A TW092101618A TW92101618A TW200302105A TW 200302105 A TW200302105 A TW 200302105A TW 092101618 A TW092101618 A TW 092101618A TW 92101618 A TW92101618 A TW 92101618A TW 200302105 A TW200302105 A TW 200302105A
- Authority
- TW
- Taiwan
- Prior art keywords
- fibrosis
- inhibitor
- skin
- scar formation
- patent application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202254.9A GB0202254D0 (en) | 2002-01-31 | 2002-01-31 | Prevention of scarring |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200302105A true TW200302105A (en) | 2003-08-01 |
Family
ID=9930135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092101618A TW200302105A (en) | 2002-01-31 | 2003-01-24 | Use of PDE5 inhibitors in the treatment of scarring |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1469857A1 (pt) |
JP (1) | JP2005523263A (pt) |
BR (1) | BR0307410A (pt) |
CA (1) | CA2474852A1 (pt) |
GB (1) | GB0202254D0 (pt) |
MX (1) | MXPA04007430A (pt) |
TW (1) | TW200302105A (pt) |
WO (1) | WO2003063875A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006528229A (ja) * | 2003-05-22 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | Pde4阻害剤及びpde5阻害剤を含有する組成物 |
CN101106997A (zh) | 2004-08-17 | 2008-01-16 | 约翰·霍普金斯大学 | Pde5抑制剂组合物及治疗心脏病征候的方法 |
ATE438403T1 (de) * | 2004-08-19 | 2009-08-15 | Switch Biotech Llc | Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen |
WO2006018088A1 (en) * | 2004-08-19 | 2006-02-23 | Switch Biotech Ag | Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders |
WO2006074443A2 (en) | 2005-01-07 | 2006-07-13 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for immunotherapy |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
WO2006111198A1 (en) * | 2005-04-18 | 2006-10-26 | Associazione Foresta Per La Ricerca Nella Riproduzione Umana | Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease |
CA2611638C (en) | 2005-06-10 | 2010-08-24 | Dong A Pharm. Co. Ltd. | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative |
AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
KR101377178B1 (ko) * | 2010-04-05 | 2014-03-26 | 에스케이케미칼주식회사 | Pde5 억제제를 함유하는 피부 주름 개선용 조성물 |
ME02207B (me) * | 2010-05-26 | 2016-02-20 | Adverio Pharma Gmbh | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) |
CN103826638B (zh) * | 2011-09-09 | 2015-11-25 | Sk化学公司 | 含有pde5 抑制剂的减少皮肤皱纹的组合物 |
AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
ES2700989T3 (es) | 2012-12-21 | 2019-02-20 | Mayo Found Medical Education & Res | Métodos y materiales para tratar estenosis de la válvula aórtica calcificada |
EP2992885A3 (en) * | 2014-09-02 | 2016-05-18 | Jansfat Biotechnology Co., Ltd. | Method for inhibiting a liver disease |
EP4166129A1 (en) | 2017-03-14 | 2023-04-19 | Atir Holding S.A. | Use of heterocyclic compounds in the treatment of aged skin |
WO2018167689A1 (en) | 2017-03-14 | 2018-09-20 | Atir Holding S.A. | Topical formulation for the treatment of pigmented skin |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5965501A (en) * | 1997-03-28 | 1999-10-12 | Lever Brothers Company, Division Of Conopco, Inc. | Personal washing bar compositions comprising emollient rich phase/stripe |
AU5067098A (en) * | 1997-11-26 | 1999-06-15 | Mochida Pharmaceutical Co., Ltd. | Pyridocarbazole derivatives with cgmp-pde inhibitory activity |
ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
GB9909135D0 (en) * | 1999-04-22 | 1999-06-16 | Univ Wales Medicine | Cystic fibrosis medicaments |
CA2323008C (en) * | 1999-10-11 | 2005-07-12 | Pfizer Inc. | Pharmaceutically active compounds |
GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
-
2002
- 2002-01-31 GB GBGB0202254.9A patent/GB0202254D0/en not_active Ceased
-
2003
- 2003-01-21 EP EP20030734608 patent/EP1469857A1/en not_active Withdrawn
- 2003-01-21 JP JP2003563565A patent/JP2005523263A/ja active Pending
- 2003-01-21 MX MXPA04007430A patent/MXPA04007430A/es unknown
- 2003-01-21 BR BR0307410-2A patent/BR0307410A/pt not_active IP Right Cessation
- 2003-01-21 WO PCT/IB2003/000134 patent/WO2003063875A1/en active Application Filing
- 2003-01-21 CA CA002474852A patent/CA2474852A1/en not_active Abandoned
- 2003-01-24 TW TW092101618A patent/TW200302105A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA04007430A (es) | 2005-06-20 |
JP2005523263A (ja) | 2005-08-04 |
BR0307410A (pt) | 2004-12-28 |
GB0202254D0 (en) | 2002-03-20 |
EP1469857A1 (en) | 2004-10-27 |
CA2474852A1 (en) | 2003-08-07 |
WO2003063875A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200302105A (en) | Use of PDE5 inhibitors in the treatment of scarring | |
US20190314352A1 (en) | Administration of dipeptidyl peptidase inhibitors | |
AU2004200573B2 (en) | Method of Treating Nitrate-induced Tolerance | |
US8669257B2 (en) | Phenazine derivatives and uses thereof as potassium channel modulators | |
US20040186046A1 (en) | Treatment of type 1 diabetes with PDE5 inhibitors | |
WO2000064478A1 (fr) | Medicaments destines a soigner et a prevenir les maladies du foie | |
US20030125337A1 (en) | Inhibitors of multidrug transporters | |
HUE028008T2 (en) | sGC stimulators or sGC activators alone and in combination with PDE5 inhibitors for the treatment of cystic fibrosis | |
JP2007169278A (ja) | Luts処置用の医薬組合せ | |
JP2003525240A (ja) | 糖尿病性腎障害の処置のためのpdgf受容体チロシンキナーゼ阻害剤の使用 | |
CN108430475B (zh) | 用于治疗慢性咳嗽的奥维匹坦 | |
US20080188497A1 (en) | Dipyridamole, Acetylsalicylic Acid, and Angiotensin II Antagonist Pharmaceutical Compositions | |
CZ20032705A3 (en) | Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders | |
TW201006823A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
JP2009520806A (ja) | PDE−5阻害薬と5−α還元酵素阻害薬の医薬組合せ | |
US20030216407A1 (en) | Use of PDE5 inhibitors in the treatment of scarring | |
EP1293213A1 (en) | Preventives/remedies for postoperative stress | |
JP2005529927A (ja) | 新規な組み合わせ | |
JP2006520777A (ja) | Pde5阻害剤を用いる1型糖尿病の治療 | |
JP2005531627A (ja) | 新規混合医薬 | |
KR20230145439A (ko) | Irak4 분해제 및 이의 용도 | |
US20040132731A1 (en) | Novel combination | |
WO2005042022A2 (en) | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist | |
JP2004519425A (ja) | 創傷の治療 | |
JP2001354656A (ja) | ヒドロキシホルムアミジン化合物及びその塩並びにそれらを含む医薬 |